9-Cyclopentyladenine

CAS No. 715-91-3

9-Cyclopentyladenine( —— )

Catalog No. M34489 CAS No. 715-91-3

9-Cyclopentyladenine (NSC-19486) is an adenylate cyclase inhibitor that blocks cellular morphological differentiation and phosphorylation of specific signaling molecules.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 409 In Stock
10MG 604 In Stock
25MG 938 In Stock
50MG 1265 In Stock
100MG 1702 In Stock
200MG Get Quote In Stock
500MG 3422 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    9-Cyclopentyladenine
  • Note
    Research use only, not for human use.
  • Brief Description
    9-Cyclopentyladenine (NSC-19486) is an adenylate cyclase inhibitor that blocks cellular morphological differentiation and phosphorylation of specific signaling molecules.
  • Description
    9-Cyclopentyladenine (NSC-19486) is an adenylate cyclase inhibitor that blocks cellular morphological differentiation and phosphorylation of specific signaling molecules.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    AChR
  • Recptor
    AChR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    715-91-3
  • Formula Weight
    203.24
  • Molecular Formula
    C10H13N5
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    NC1=C2C(N(C=N2)C3CCCC3)=NC=N1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Mitotan

    Mitotane(2,4′-DDD), an isomer of DDD and derivative of DDT, is an antineoplastic medication used in the treatment of adrenocortical carcinoma.

  • VU0152100

    VU0152100 is an effective and selective allosteric potentiator of M4 mAChR (EC50: 380 ± 93 nM).

  • Xanomeline

    Xanomeline (LY-246708) is a functionally selective M1/M4 activator used in the study of neurological disorders such as schizophrenia and has shown promising treatment in preclinical trials.